1-20 of 27
Raquel Izumi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

VIP152 Is a Novel CDK9 Inhibitor with Efficacy in Chronic Lymphocytic Leukemia

Steven Sher, Larry Beaver, Katie Williams, Shelley Orwick, Brandi R. Walker, Charles Thomas Gregory, Matthew Purcell, Alexander Pan, Pearlly S. Yan, Amy J. Johnson, Melanie M. Frigault, Joy M. Greer, Ahmed Hamdy, Raquel Izumi, Stuart Hwang, James S. Blachly, John C. Byrd, Rosa Lapalombella
Journal: Blood
Blood (2021) 138 (Supplement 1): 270.
DOI: https://doi.org/10.1182/blood-2021-153812
Published: 2021
Journal Articles

VIP152, a Selective CDK9 Inhibitor, Induces Complete Regression in a High-Grade B-Cell Lymphoma (HGBL) Model and Depletion of Short-Lived Oncogenic Driver Transcripts, MYC and MCL1, with a Once Weekly Schedule

Melanie M. Frigault, Harvey Wong, Hermes Garban, Joy M. Greer, Stuart Hwang, Raquel Izumi, Amy J. Johnson, Beatrix Stelte-Ludwig, Ahmed Hamdy
Journal: Blood
Blood (2021) 138 (Supplement 1): 1192.
DOI: https://doi.org/10.1182/blood-2021-150917
Published: 2021
Journal Articles

Acalabrutinib in treatment-naive chronic lymphocytic leukemia

Clinical Trials & Observations
John C. Byrd, Jennifer A. Woyach, Richard R. Furman, Peter Martin, Susan O’Brien, Jennifer R. Brown, Deborah M. Stephens, Jacqueline C. Barrientos, Stephen Devereux, Peter Hillmen, John M. Pagel, Ahmed Hamdy, Raquel Izumi, Priti Patel, Min Hui Wang, Nitin Jain, William G. Wierda
Journal: Blood
Blood (2021) 137 (24): 3327–3338.
DOI: https://doi.org/10.1182/blood.2020009617
Published: 2021
Includes: Supplemental data
Journal Articles

Ibrutinib Off-Target Inhibition Inhibits Antibody-Dependent Cellular Phagocytosis but Not Efferocytosis of CLL Cells

Charles C. Chu, PhD, Jonathan J. Pinney, PhD, Sara K. Blick-Nitko, MS, Andrea M. Baran, MS, Derick R. Peterson, PhD, Hannah E. Whitehead, Raquel Izumi, PhD, Veerendra Munugalavadla, PhD, Paul M. Barr, MD, Karl R. VanDerMeid, BS, Michael Rusty Elliott, PhD, Clive S. Zent, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 45.
DOI: https://doi.org/10.1182/blood-2020-139483
Published: 2020
Journal Articles

Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib

Clinical Trials & Observations
Clare Sun, Pia Nierman, Ellen K. Kendall, Jean Cheung, Michael Gulrajani, Sarah E. M. Herman, Christopher Pleyer, Inhye E. Ahn, Maryalice Stetler-Stevenson, Constance M. Yuan, Irina Maric, Erika M. Gaglione, Hailey M. Harris, Stefania Pittaluga, Min Hui Wang, Priti Patel, Mohammed Z. H. Farooqui, Raquel Izumi, Ahmed Hamdy, Todd Covey, Adrian Wiestner
Journal: Blood
Blood (2020) 136 (1): 93–105.
DOI: https://doi.org/10.1182/blood.2019003715
Published: 2020
Includes: Supplemental data
Journal Articles

Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results

Clinical Trials & Observations
John C. Byrd, William G. Wierda, Anna Schuh, Stephen Devereux, Jorge M. Chaves, Jennifer R. Brown, Peter Hillmen, Peter Martin, Farrukh T. Awan, Deborah M. Stephens, Paolo Ghia, Jacqueline Barrientos, John M. Pagel, Jennifer A. Woyach, Kathleen Burke, Todd Covey, Michael Gulrajani, Ahmed Hamdy, Raquel Izumi, Melanie M. Frigault, Priti Patel, Wayne Rothbaum, Min Hui Wang, Susan O’Brien, Richard R. Furman
Journal: Blood
Blood (2020) 135 (15): 1204–1213.
DOI: https://doi.org/10.1182/blood.2018884940
Published: 2020
Includes: Supplemental data
Journal Articles

Anti-CD20 Therapy Reliance on Antibody-Dependent Cellular Phagocytosis Affects Combination Drug Choice

Charles C. Chu, PhD, Jonathan J. Pinney, MS, Karl R. VanDerMeid, BS, Raquel Izumi, PhD, Veerendra Munugalavadla, PhD, Paul M. Barr, MD, Michael Rusty Elliott, PhD, Clive S Zent, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 682.
DOI: https://doi.org/10.1182/blood-2019-124901
Published: 2019
Journal Articles

ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL)

Jeff P. Sharman, MD, Versha Banerji, MD, Laura Maria Fogliatto, MD PhD, Yair Herishanu, MD, Talha Munir, MD, Renata Walewska, George Follows, Karin Karlsson, MD, Paolo Ghia, MD PhD, Gillian Corbett, Patricia Walker, MBBS, Miklos Egyed, Wojciech Jurczak, MD PhD, Gilles Salles, MD PhD, Ann Janssens, Florence Cymbalista, MD PhD, William G. Wierda, MD PhD, Steven Coutre, MD, John M. Pagel, MD PhD DSc, Alan Skarbnik, MD, Manali Kamdar, MD, Jennifer Woyach, MD, Raquel Izumi, PhD, Veerendra Munugalavadla, PhD, Priti Patel, MD, Min Hui Wang, PhD, Sofia Wong, John C. Byrd, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 31.
DOI: https://doi.org/10.1182/blood-2019-128404
Published: 2019
Journal Articles

PRISM: A Platform Protocol for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma

Mark Roschewski, MD, Raquel Izumi, PhD, Ahmed Hamdy, MD, Manish R. Patel, MD, Hendrik-Tobias Arkenau, MD PhD, Sven de Vos, MD PhD, Patrick M Reagan, MD, Pier Luigi Zinzani, MD PhD, Andrew Davies, MD PhD, John M Pagel, MD PhD, Julie M Vose, MDMBA, Bojena Bitman, Graham Brock, PhD, Edwin Clark, PhD, Melanie M. Frigault, PhD, Joseph Ware, PhD, Buyue Yang, MD PhD, Wyndham Wilson, MD, Louis Staudt, MD, Ian W. Flinn, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2869.
DOI: https://doi.org/10.1182/blood-2019-125939
Published: 2019
Journal Articles

Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: 42-Month Follow-up of a Phase 2 Study

Richard R. Furman, MD, William G. Wierda, MD PhD, Anna Schuh, Stephen Devereux, PhD, Jorge M. Chaves, MD, Jennifer R. Brown, MD PhD, Peter Hillmen, MD PhD, Peter Martin, FRCPC, MD MS, Farrukh T Awan, MD, Deborah M. Stephens, DO, Paolo Ghia, MD PhD, Jacqueline C. Barrientos, MD MS, John M. Pagel, MD PhD DSc, Jennifer Woyach, MD, Kathleen Burke, PhD, Todd Covey, Michael Gulrajani, Ahmed Hamdy, MD, Raquel Izumi, PhD, Melanie M. Frigault, PhD, Priti Patel, MD, Wayne Rothbaum, Min Hui Wang, PhD, Susan M. O'Brien, MD, John C. Byrd, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3039.
DOI: https://doi.org/10.1182/blood-2019-128706
Published: 2019
Journal Articles

Acalabrutinib in Patients with Relapsed/Refractory (R/R) and High-Risk, Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL)

Clare C. Sun, MD, Pia Nierman, RN, Inhye E. Ahn, MD, Janet Valdez, Jennifer Lotter, Susan Soto, Sarah E. M. Herman, PhD, Todd Covey, PhD, Ahmed Hamdy, MD, Raquel Izumi, PhD, Dongmei Liu, PhD, Priti Patel, MD, Adrian Wiestner, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4424.
DOI: https://doi.org/10.1182/blood-2018-99-110395
Published: 2018
Journal Articles

Partial Reconstitution of Humoral and Cellular Immunity in Patients with Chronic Lymphocytic Leukemia Treated with Acalabrutinib

Christopher Pleyer, MD, Clare C. Sun, MD, Pia Niermann, Xin Tian, Inhye E. Ahn, MD, Janet Valdez, Jennifer Lotter, Raquel Izumi, PhD, Ahmed Hamdy, MD, Adrian Wiestner, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1874.
DOI: https://doi.org/10.1182/blood-2018-99-111919
Published: 2018
Journal Articles

Variable Bruton Tyrosine Kinase (BTK) Resynthesis across Patients with Chronic Lymphocytic Leukemia (CLL) on Acalabrutinib Therapy Affect Target Occupancy and Reactivation of B-Cell Receptor (BCR) Signaling

Anfal A. Alsadhan, Jean Cheung, Michael Gulrajani, Erika M. Cook, Stefania Pittaluga, MD PhD, Theresa Davies-Hill, Raquel Izumi, PhD, Clare C. Sun, MD, Todd Covey, PhD, Adrian Wiestner, MD, Sarah E. M. Herman, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4401.
DOI: https://doi.org/10.1182/blood-2018-99-110391
Published: 2018
Journal Articles

Long-Term Follow-up of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma

Michael Wang, MD, Simon Rule, MD, Pier Luigi Zinzani, MD, Andre Goy, MD, Olivier Casasnovas, MD, Stephen D. Smith, MD, Gandhi Damaj, MD PhD, Jeanette K. Doorduijn, MD PhD, Thierry Lamy, Franck Morschhauser, MD, Carlos Panizo, MD PhD, Bijal D. Shah, MD, Andrew Davies, Richard Eek, MBCHB, Jehan Dupuis, MD, Eric Jacobsen, MD, Arnon P. Kater, MD PhD, Steven LE Gouill, MD PhD, Lucie Oberic, MD, Tadeusz Robak, MD PhD, Richa Dua, PharmD, Melanie M. Frigault, PhD, Raquel Izumi, PhD, Dorothy Nguyen, MD PhD, Priti Patel, MD, Ming Yin, PhD, Wojciech Jurczak, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2876.
DOI: https://doi.org/10.1182/blood-2018-99-110327
Published: 2018
Journal Articles

Acalabrutinib in Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL): Updated Results from the Phase 1/2 ACE-CL-001 Study

John C. Byrd, MD, Jennifer A. Woyach, MD, Richard R. Furman, MD, Peter Martin, FRCPC, MD MS, Susan M. O'Brien, MD, Jennifer R. Brown, MD PhD, Deborah M. Stephens, Jacqueline C. Barrientos, MD, Stephen Devereux, PhD, Peter Hillmen, MB ChB, PhD FRCP, FRCPath, John M. Pagel, MD PhD, Dih-Yih Chen, MD, Ahmed Hamdy, MD, Raquel Izumi, PhD, Priti Patel, MD, Min Hui Wang, PhD, Nitin Jain, MD, William G. Wierda, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 692.
DOI: https://doi.org/10.1182/blood-2018-99-110451
Published: 2018
Journal Articles

Efficacy and Safety of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma in the Phase 2 ACE-LY-004 Study

Michael Wang, MD, Simon Rule, MD, Pier Luigi Zinzani, MD PhD, Andre Goy, MD, Rene-Olivier Casasnovas, MD, Stephen D. Smith, MD, Gandhi Damaj, MD, Jeanette K. Doorduijn, MD PhD, Thierry Lamy, Pr, MD PhD, Franck Morschhauser, MD PhD, Carlos Panizo, MD PhD, Bijal Shah, MD, Andrew Davies, PhD, Richard Eek, MBCHB, Jehan Dupuis, MD, Eric Jacobsen, MD, Arnon P. Kater, MD PhD, Steven Le Gouill, MDPhD, Lucie Oberic, MD, Tadeusz Robak, MD PhD, Todd Covey, PhD, Richa Dua, PharmD, Ahmed Hamdy, MD, Xin Huang, Raquel Izumi, PhD, Priti Patel, MD, J. Greg Slatter, PhD, Wojciech Jurczak, PhDMD
Journal: Blood
Blood (2017) 130 (Supplement 1): 155.
DOI: https://doi.org/10.1182/blood.V130.Suppl_1.155.155
Published: 2017
Journal Articles

Pharmacodynamic Evaluation of Acalabrutinib in Relapsed/Refractory and Treatment-Naive Patients with Chronic Lymphocytic Leukemia (CLL) in the Phase 1/2 ACE-CL-001 Study

Todd Covey, PhD, Michael Gulranjani, Jean Cheung, Elena Bibikova, Tracy Clevenger, Fanny Krantz, Karen Pan, Kyoko Yamaguchi, Anouk De Jong, Bart Van Lith, Diana Mittag, Raquel Izumi, PhD, John C. Byrd, MD, William G Wierda, MD PhD, Susan M. O'Brien, MD, Richard R. Furman, MD, Allard Kaptein, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1741.
DOI: https://doi.org/10.1182/blood.V130.Suppl_1.1741.1741
Published: 2017
Journal Articles

CYP3A-Mediated Drug Interaction Profile of Bruton Tyrosine Kinase Inhibitor, Acalabrutinib

Raquel Izumi, PhD, Paul G. Pearson, PhD, Ahmed Hamdy, MD, Sara Rodriquez, MHA, Yolanda Y.L. Yang, MD PhD, Roger G. Ulrich, PhD, Terry Podoll, PhD, Marilee Andrew, PhD, Cecile M. Krejsa, PhD, Tim Ingallinera, BSc, J. Greg Slatter, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4996.
DOI: https://doi.org/10.1182/blood.V130.Suppl_1.4996.4996
Published: 2017
Journal Articles

Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Updated Results from the Phase 1/2 ACE-CL-001 Study

John C. Byrd, MD, William G Wierda, MD PhD, Anna Schuh, MD PhD, Stephen Devereux, FRCP, FRCPath, PhD, Jorge M. Chaves, MD, Jennifer R. Brown, MD PhD, Peter Hillmen, MBChB, PhD, Peter Martin, MD, Farrukh T. Awan, MD MS, Deborah M. Stephens, DO, Paolo Ghia, MD PhD, Jacqueline C. Barrientos, MD, John M. Pagel, MD PhD, Jennifer A. Woyach, MD, Prista Charuworn, MD, Ahmed Hamdy, MD, Raquel Izumi, PhD, Priti Patel, MD, Wayne M. Rothbaum, Min Hui Wang, PhD, Richard R. Furman, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 498.
DOI: https://doi.org/10.1182/blood.V130.Suppl_1.498.498
Published: 2017
Journal Articles

Acalabrutinib with Obinutuzumab in Relapsed/Refractory and Treatment-Naive Patients with Chronic Lymphocytic Leukemia: The Phase 1b/2 ACE-CL-003 Study

Jennifer A. Woyach, MD, Farrukh T. Awan, MD MS, Mojgan Jianfar, MD, Kerry A. Rogers, MD, Jeffrey Jones, MD MPH, Todd Covey, PhD, Ahmed Hamdy, MD, Raquel Izumi, PhD, Priti Patel, MD, Min Hui Wang, PhD, John C. Byrd, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 432.
DOI: https://doi.org/10.1182/blood.V130.Suppl_1.432.432
Published: 2017